Metformin: Taking away the candy for cancer?

Warburg, 1956, On the origin of cancer cells, Science, 123, 309, 10.1126/science.123.3191.309 Vijg, 2008, Puzzles, promises and a cure for ageing, Nature, 454, 1065, 10.1038/nature07216 Towler, 2007, AMP-activated protein kinase in metabolic control and insulin signaling, Circ Res, 100, 328, 10.1161/01.RES.0000256090.42690.05 King, 1998, Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections, Diabetes Care, 21, 1414, 10.2337/diacare.21.9.1414 Godsland, 2009, Insulin resistance and hyperinsulinaemia in the development and progression of cancer, Clin Sci (Lond), 118, 315, 10.1042/CS20090399 Hjalgrim, 1997, Cancer and diabetes. A follow-up study of two population-based cohorts of diabetic patients, J Intern Med, 241, 471, 10.1111/j.1365-2796.1997.tb00004.x Goodwin, 2002, Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study, J Clin Oncol, 20, 42, 10.1200/JCO.20.1.42 Barone, 2008, Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis, JAMA, 300, 2754, 10.1001/jama.2008.824 Jiralerspong, 2009, Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer, J Clin Oncol, 27, 3297, 10.1200/JCO.2009.19.6410 Pollak, 2008, Insulin and insulin-like growth factor signalling in neoplasia, Nat Rev Cancer, 8, 915, 10.1038/nrc2536 Koohestani, 1997, Insulin resistance and promotion of aberrant crypt foci in the colons of rats on a high-fat diet, Nutr Cancer, 29, 69, 10.1080/01635589709514604 Tran, 1996, Insulin promotion of colon tumors in rats, Cancer Epidemiol Biomarkers Prev, 5, 1013 Bowker, 2006, Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin, Diabetes Care, 29, 254, 10.2337/diacare.29.02.06.dc05-1558 Chlebowski, 2008, Survival analyses from the Women’s Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome, JCO, 26, 522, 10.1200/jco.2008.26.15_suppl.522 Frasca, 2008, The role of insulin receptors and IGF-I receptors in cancer and other diseases, Arch Physiol Biochem, 114, 23, 10.1080/13813450801969715 Mountjoy, 1987, Abnormal insulin-receptor down regulation and dissociation of down regulation from insulin biological action in cultured human tumor cells, Cancer Res, 47, 6500 Papa, 1996, Insulin receptors in breast cancer: biological and clinical role, J Endocrinol Invest, 19, 324, 10.1007/BF03347871 De Meyts, 2004, Insulin and its receptor: structure, function and evolution, Bioessays, 26, 1351, 10.1002/bies.20151 Ibrahim, 2004, Insulin-like growth factor-I and cancer risk, Growth Horm IGF Res, 14, 261, 10.1016/j.ghir.2004.01.005 Leung, 2000, Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation, J Clin Endocrinol Metab, 85, 4712, 10.1210/jc.85.12.4712 Clemmons, 2007, Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes, J Clin Endocrinol Metab, 92, 2652, 10.1210/jc.2006-2699 Snyder, 1990, Insulin-dependent regulation of insulin-like growth factor-binding protein-1, J Clin Endocrinol Metab, 71, 1632, 10.1210/jcem-71-6-1632 Wu, 2002, Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis, Cancer Res, 62, 1030 Yu, 2000, Role of the insulin-like growth factor family in cancer development and progression, J Natl Cancer Inst, 92, 1472, 10.1093/jnci/92.18.1472 Plymate, 1988, Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin, J Clin Endocrinol Metab, 67, 460, 10.1210/jcem-67-3-460 Pugeat, 1991, Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin, J Steroid Biochem Mol Biol, 40, 841, 10.1016/0960-0760(91)90310-2 Tok, 2004, The androgenic profile of women with non-insulin-dependent diabetes mellitus, J Reprod Med, 49, 746 Vikan, 2010, Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men, Eur J Endocrinol, 162, 747, 10.1530/EJE-09-0943 Shoelson, 2006, Inflammation and insulin resistance, J Clin Invest, 116, 1793, 10.1172/JCI29069 Festa, 2002, Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study, Diabetes, 51, 1131, 10.2337/diabetes.51.4.1131 Housa, 2006, Adipocytokines and cancer, Physiol Res, 55, 233, 10.33549/physiolres.930848 Mantovani, 2008, Cancer-related inflammation, Nature, 454, 436, 10.1038/nature07205 Shaw, 2005, The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin, Science, 310, 1642, 10.1126/science.1120781 Stapleton, 1996, Mammalian AMP-activated protein kinase subfamily, J Biol Chem, 271, 611, 10.1074/jbc.271.2.611 Shaw, 2004, The LKB1 tumor suppressor negatively regulates mTOR signaling, Cancer Cell, 6, 91, 10.1016/j.ccr.2004.06.007 Guertin, 2007, Defining the role of mTOR in cancer, Cancer Cell, 12, 9, 10.1016/j.ccr.2007.05.008 Alimova, 2009, Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro, Cell cycle, 8, 909, 10.4161/cc.8.6.7933 Ben Sahra, 2008, The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level, Oncogene, 27, 3576, 10.1038/sj.onc.1211024 Gotlieb, 2008, In vitro metformin anti-neoplastic activity in epithelial ovarian cancer, Gynecol Oncol, 110, 246, 10.1016/j.ygyno.2008.04.008 Zakikhani, 2006, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells, Cancer Res, 66, 10269, 10.1158/0008-5472.CAN-06-1500 Goodwin, 2008, Insulin-lowering effects of metformin in women with early breast cancer, Clin Breast Cancer, 8, 501, 10.3816/CBC.2008.n.060 Ning, 2010, AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation, Mol Endocrinol, 24, 1218, 10.1210/me.2009-0474 Rozengurt, 2010, Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer, Clin Cancer Res, 16, 2505, 10.1158/1078-0432.CCR-09-2229 Inoki, 2003, TSC2 mediates cellular energy response to control cell growth and survival, Cell, 115, 577, 10.1016/S0092-8674(03)00929-2 Morgensztern, 2005, PI3K/Akt/mTOR pathway as a target for cancer therapy, Anticancer Drugs, 16, 797, 10.1097/01.cad.0000173476.67239.3b Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 2010 [Epub ahead of print]. Vazquez-Martin, 2009, The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells, Cell Cycle, 8, 88, 10.4161/cc.8.1.7499 Vazquez-Martin, 2009, The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy, Ann Oncol, 20, 592, 10.1093/annonc/mdn758 Shell, 2008, Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells, Cell Cycle, 7, 1769, 10.4161/cc.7.12.6016 Ersoy, 2008, The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients, Diabetes Res Clin Pract, 81, 56, 10.1016/j.diabres.2008.02.006 Lund, 2008, Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes, Eur J Endocrinol, 158, 631, 10.1530/EJE-07-0815 Phoenix, 2009, Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model, Breast Cancer Res Treat, 113, 101, 10.1007/s10549-008-9916-5 Stambolic, 2009, Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?, Breast Cancer Res Treat, 114, 387, 10.1007/s10549-008-0015-4 Minamino, 2009, A crucial role for adipose tissue p53 in the regulation of insulin resistance, Nat Med, 15, 1082, 10.1038/nm.2014 Thoreen, 2005, AMPK and p53 help cells through lean times, Cell Metab, 1, 287, 10.1016/j.cmet.2005.04.009 Ben Sahra, 2010, Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells, Cancer Res, 70, 2465, 10.1158/0008-5472.CAN-09-2782 Buzzai, 2007, Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth, Cancer Res, 67, 6745, 10.1158/0008-5472.CAN-06-4447 Oliveras-Ferraros, 2009, Genome-wide inhibitory impact of the AMPK activator metformin on M-phase cell cycle genes in human breast cancer cells, Cell Cycle, 8, 1633, 10.4161/cc.8.10.8406 de Jager, 2010, Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial, BMJ, 340, c2181, 10.1136/bmj.c2181 Garcia, 2010, Metformin, B(12), and enhanced breast cancer response to chemotherapy, J Clin Oncol, 28, e19, 10.1200/JCO.2009.25.7857 Algire, 2008, Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth, Endocr Relat Cancer, 15, 833, 10.1677/ERC-08-0038 Bojkova, 2009, Metformin in chemically-induced mammary carcinogenesis in rats, Neoplasma, 56, 269, 10.4149/neo_2009_03_269 Anisimov, 2005, Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice, Exp Gerontol, 40, 685, 10.1016/j.exger.2005.07.007 Evans, 2005, Metformin and reduced risk of cancer in diabetic patients, BMJ, 330, 1304, 10.1136/bmj.38415.708634.F7 Landman, 2010, Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16, Diabetes Care, 33, 322, 10.2337/dc09-1380 Libby, 2009, New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes, Diabetes Care, 32, 1620, 10.2337/dc08-2175 Hernandez-Diaz, 2010, Diabetes therapy and cancer risk: causal effects and other plausible explanations, Diabetologia, 53, 802, 10.1007/s00125-010-1675-2 Shu, 2007, Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action, J Clin Invest, 117, 1422, 10.1172/JCI30558 Hayer-Zillgen, 2002, Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3, Br J Pharmacol, 136, 829, 10.1038/sj.bjp.0704785 Legro, 2008, Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene, J Clin Endocrinol Metab, 93, 792, 10.1210/jc.2007-1736 Hezel, 2008, LKB1; linking cell structure and tumor suppression, Oncogene, 27, 6908, 10.1038/onc.2008.342 Cool, 2006, Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome, Cell Metab, 3, 403, 10.1016/j.cmet.2006.05.005 Iozzo, 2003, Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes, Diabetes Care, 26, 2069, 10.2337/diacare.26.7.2069 Virtanen, 2003, Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects, Diabetes, 52, 283, 10.2337/diabetes.52.2.283 Hallsten, 2004, Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone, Diabet Med, 21, 1280, 10.1111/j.1464-5491.2004.01332.x Gontier, 2008, High and typical 18F-FDG bowel uptake in patients treated with metformin, Eur J Nucl Med Mol Imaging, 35, 95, 10.1007/s00259-007-0563-6 van Dijk TH, Laskewitz AJ, Boer TS, et al. Computational analysis of carbohydrate metabolism. 2010;9:177–94. Larsson, 2006, Diabetes mellitus and risk of bladder cancer: a meta-analysis, Diabetologia, 49, 2819, 10.1007/s00125-006-0468-0 Larsson, 2007, Diabetes mellitus and risk of breast cancer: a meta-analysis, Int J Cancer, 121, 856, 10.1002/ijc.22717 Wolf, 2005, Diabetes mellitus and breast cancer, Lancet Oncol, 6, 103, 10.1016/S1470-2045(05)01736-5 Larsson, 2005, Diabetes mellitus and risk of colorectal cancer: a meta-analysis, J Natl Cancer Inst, 97, 1679, 10.1093/jnci/dji375 Friberg, 2007, Diabetes mellitus and risk of endometrial cancer: a meta-analysis, Diabetologia, 50, 1365, 10.1007/s00125-007-0681-5 El-Serag, 2006, The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence, Clin Gastroenterol Hepatol, 4, 369, 10.1016/j.cgh.2005.12.007 Chao, 2008, Type 2 diabetes mellitus and risk of non-Hodgkin lymphoma: a systematic review and meta-analysis, Am J Epidemiol, 168, 471, 10.1093/aje/kwn160 Mitri, 2008, Diabetes and risk of Non-Hodgkin’s lymphoma: a meta-analysis of observational studies, Diabetes Care, 31, 2391, 10.2337/dc08-1034 Everhart, 1995, Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis, JAMA, 273, 1605, 10.1001/jama.1995.03520440059037 Huxley, 2005, Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies, Br J Cancer, 92, 2076, 10.1038/sj.bjc.6602619 Bonovas, 2004, Diabetes mellitus and risk of prostate cancer: a meta-analysis, Diabetologia, 47, 1071, 10.1007/s00125-004-1415-6 Kasper, 2006, A meta-analysis of diabetes mellitus and the risk of prostate cancer, Cancer Epidemiol Biomarkers Prev, 15, 2056, 10.1158/1055-9965.EPI-06-0410 Martin-Castillo, 2010, Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology, Ann Oncol, 21, 187, 10.1093/annonc/mdp494 Muti, 2009, Metformin diet, breast cancer: an avenue for chemoprevention, Cell Cycle, 8, 2661, 10.4161/cc.8.16.9226 Cazzaniga, 2009, Is it time to test metformin in breast cancer clinical trials?, Cancer Epidemiol Biomarkers Prev, 18, 701, 10.1158/1055-9965.EPI-08-0871